Florida Cancer Specialists report indicates negative impact of step therapy in oncology
Physician leaders at Florida Cancer Specialists & Research Institute report that insurer-mandated step therapy policies are creating significant treatment delays and health risks for oncology patients.
A comprehensive internal review by Florida Cancer Specialists & Research Institute (FCSRI) has identified significant clinical complications arising from insurer-driven step therapy protocols. These policies often require patients to try lower-cost medications before receiving the specific treatments originally prescribed by their oncologists.
According to the report, such administrative hurdles frequently result in treatment delays, which the study suggests can negatively influence long-term health outcomes for those battling cancer. The leadership team at FCSRI emphasizes that these requirements frequently disrupt established care plans and increase the administrative burden on clinical staff.
The findings add data to an ongoing national debate regarding the balance between health insurance cost-containment measures and clinical autonomy. As insurers push for greater use of step therapy to manage pharmacy benefits, oncologists are increasingly concerned that administrative policies are taking precedence over individualized medical decision-making.